Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹192.4 Cr
verification pending
Revenue YoY
-40%
reported change
EBITDA
Pending
latest reported figure
Source
manual review required
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Blue Jet Healthcare reported a sharp 40% YoY decline in Q3 FY26 revenue to ₹192.4 crore, with EBITDA down 62% and PAT down 39%, driven by destocking in the key pharma intermediate (bempedoic acid) and supply chain realignment. Contrast media revenue was flat sequentially despite strong dispatches, with goods-in-transit normalization expected in Q4. Gross margin contracted to 52% due to product mix and a 1% inventory write-off. Management guided that destocking may persist for another quarter or two, but remains confident in FY27 recovery backed by three large contrast media molecules (NC intermediate, iodinated product, backward integration unit) and a ₹1,000 crore greenfield capex at Visakhapatnam. Key risk: the bempedoic acid supply chain realignment could lead to permanent volume loss if the innovator shifts share to new suppliers.
Colored figures show movement against the previous available record.
Guidance to track
- The new block for contrast media intermediates is nearing completion and expected to be ready for qualification in Q1 FY27, improving cost competitiveness.
- Board-approved ₹1,000 crore investment for a greenfield site, with phase one dedicated to API and intermediates aligned with customer demand.
- Lease secured for R&D activities in Hyderabad; development work expected to commence from Q3 FY27, focusing on GLP-1 intermediates, peptide chemistry, and biocatalysis.
- Exhibit batches of a new artificial sweetener will be initiated in FY27, complementing the existing high-intensity sweetener portfolio.
Risks flagged
- Management acknowledged destocking and supply chain realignment for bempedoic acid, but did not quantify the impact or confirm when volumes will normalize. Analyst raised concern about potential permanent loss of market share.
- Gross margin fell to 52% in Q3 due to product mix and a 1% inventory write-off. Management guided a wide 50-55% range, indicating uncertainty.
- Despite diversification efforts, a significant portion of revenue still depends on a few molecules, making the company vulnerable to order lumpiness.
- The large greenfield capex may strain cash flows; management mentioned options including debt or equity dilution, but no firm plan was provided.
Key quotes
- We believe the scale, infrastructure and the geographic advantage of VISAC will strengthen positioning as a reliable global partner in complex chemistries.
- These are very sticky relations and in most of these cases these are backed by multi-year supply agreements.
- We have been supplying we have supplied large quantities in the past... huge quantities have been supplied by us in the past and um uh so that's the momentum that I'm talking about.
Research modules